---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-24-000091"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:52:13.390558+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q1 net loss $52.2M; interim TAMARACK data shows vobra duo activity in mCRPC

## Summary
- Q1 net loss $52.2M ($0.84/share) vs $38.0M loss in Q1 2023; total revenue $9.1M, down from $24.5M.
- Cash, equivalents and marketable securities $184.2M as of March 31, 2024; cash runway expected into 2026.
- Interim TAMARACK data: vobra duo 2.0 mg/kg q4W showed confirmed PSA≥50% reduction in 36/82 (43.9%) and ORR of 17.8%.
- Five fatal AEs reported in TAMARACK; two pneumonitis deaths in 2.7 mg/kg cohort; Phase 3 planning initiated for 2025.
- Company plans to expand TAMARACK to NSCLC, SCLC, melanoma and other indications in mid-2024.

## SEC filing metadata
- accession: 0001125345-24-000091
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/0001125345-24-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/mgnx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-24-000091
- JSON: https://secwatch.observer/filing/0001125345-24-000091.json
- Plain text: https://secwatch.observer/filing/0001125345-24-000091.txt

## Key facts
- Earnings Releases
  MACROGENICS INC reported financial results for quarter ended March 31, 2024.
  - Period: quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/0001125345-24-000091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.